SLXN
Income statement / Annual
Last year (2025), Silexion Therapeutics Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Silexion Therapeutics Corp's net income was -$11.91 M.
See Silexion Therapeutics Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$7.14 M
|
$5.82 M
|
$3.71 M
|
$3.23 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$4.48 M
|
$6.73 M
|
$928.00 K
|
$577.00 K
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.48 M
|
$6.73 M
|
$928.00 K
|
$577.00 K
|
$943.93 K
|
$195.86 K
|
| Other Expenses |
-$23.25 M
|
$25.00 K
|
$45.00 K
|
$57.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
-$11.63 M
|
$12.57 M
|
$4.68 M
|
$3.86 M
|
$943.93 K
|
$195.86 K
|
| Cost And Expenses |
-$11.63 M
|
$12.57 M
|
$4.68 M
|
$3.86 M
|
$943.93 K
|
$195.86 K
|
| Interest Income |
$142.00 K
|
$1.00 K
|
$153.00 K
|
$114.00 K
|
$6.37 K
|
$0.00
|
| Interest Expense |
$13.00 K
|
$52.00 K
|
$9.00 K
|
$85.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$14.00 K
|
$25.00 K
|
$45.00 K
|
$57.00 K
|
$0.00
|
$0.00
|
| EBITDA |
-$11.88 M |
-$16.48 M |
-$5.02 M |
-$3.32 M |
-$755.00 K |
-$195.86 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$23.54 M
|
-$3.94 M
|
-$395.00 K
|
$396.00 K
|
$188.72 K
|
$0.00
|
| Income Before Tax |
-$11.91 M
|
-$16.51 M
|
-$5.08 M
|
-$3.46 M
|
-$755.22 K
|
-$195.86 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$3.00 K
|
$10.00 K
|
$32.00 K
|
$24.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$11.91 M
|
-$16.44 M
|
-$4.94 M
|
-$3.22 M
|
-$755.22 K
|
-$195.86 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-89.6 |
-26.4 |
-44.2 |
0.349 |
-0.458 |
-0.119 |
| EPS Diluted |
-89.6 |
-26.4 |
-44.2 |
0.349 |
-0.458 |
-0.119 |
| Weighted Average Shares Out |
$132.95 K
|
$623.85 K
|
$111.73 K
|
$1.67 M
|
$1.65 M
|
$1.65 M
|
| Weighted Average Shares Out Diluted |
$132.95 K
|
$623.85 K
|
$111.73 K
|
$1.67 M
|
$1.65 M
|
$1.65 M
|
| Link |
|
|
|
|
|
|
